Battling Breast Cancer
By targeting multiple HER-family receptors, small-molecule drugs could fill the therapeutic gaps left by Herceptin
Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Copyright © 2024 American Chemical Society
August 7, 2006 Cover
Volume 84, Issue 32
By targeting multiple HER-family receptors, small-molecule drugs could fill the therapeutic gaps left by Herceptin
Pharmaceuticals
Class Of 2005 Salaries & Jobs
Chemists' starting salaries are up a notch from 2004, but employment scene remains below par
The Next Step In Obesity Vaccines
Ghrelin vaccine permits male rats to gain less weight on usual diet
-
A Boost For Biosensors
Beefing up signal of FRET kinase biosensors makes inexpensive high-throughput screening possible
-
Price Fixers Beware
The European Union explores ways to make it easier for cartel victims to recover damages
-
Pork-Barrel Science
Congressionally legislated programs and projects circumvent traditional competitive grant process
ADVERTISEMENT
Science Concentrates
Digital Briefs
New software and websites for the chemical enterprise
